AbCellera
@AbCelleraBio
Followers
7K
Following
236
Media
237
Statuses
417
AbCellera is clinical-stage biotech company focused developing antibody-based medicines in the areas of endocrinology, women’s health, immunology and oncology
Vancouver, British Columbia
Joined January 2016
Visit our poster at ACoP 2025 Conference to learn how using Quantitative Systems Pharmacology (QSP) models can help predict and explain the diverse in vivo efficacy outcomes of T-cell engagers. Read more about our TCE platform: https://t.co/MzjyGzwHoQ
#pharmacometrics #ISoP
2
13
101
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025 https://t.co/TbKTCZxNxU
3
17
146
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025 https://t.co/hwxbpIUvL6
4
10
80
Visit our poster at #DiscoveryOnTarget in Boston to learn how our multiple T-cell engager (TCE) building blocks can be leveraged to tailor TCE design for diverse tumor targets. Read more about our TCE platform: https://t.co/J3Omoz86zJ
0
7
63
Three months of confusion. One revelation: God was listening the whole time. Get the rest of the story on my page.
0
22
191
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575 https://t.co/B4quE7ftuk
7
28
213
AbCellera to Participate at Upcoming Investor Conferences in September https://t.co/SJbMgxWvxi
3
5
95
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms https://t.co/hEsNiajncD
10
18
152
AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 https://t.co/DbVgyKDA9K
2
11
116
Some things you just never get over. ❤️
7
25
276
Visit our poster at Antibody Engineering & Therapeutics Europe 2025 to learn how we leverage multiple T-cell engager building blocks to generate molecules with in vivo efficacy. Read more about our TCE platform: https://t.co/YFZJeTspgy
#AntibodyEngineering
2
4
57
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 https://t.co/xR2K4j9696
6
19
115
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause https://t.co/SYru4rOOuJ
0
12
105
AbCellera’s Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit https://t.co/Cbvco2QIXw
5
9
83
AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting https://t.co/lMwd3cz8rM
0
9
68
Futures Traders: Profits made today are profits you can take today. Withdraw from Day 1 in PRO—no waiting, no payout windows, no delays. Stay disciplined & get paid when it’s convenient for you, not just for the firm
1
17
124
Visit our poster at #PEGSSummit to learn how multiple T-cell engager (TCE) building blocks can be leveraged to tailor TCE design for diverse tumor targets. Read more about our TCE platform: https://t.co/ftF1ZqL8do
1
1
12
Visit our poster at #SIDSanDiego25 to learn about a novel, fully human and half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis. Read more about our pipeline here: https://t.co/yn6Z19nddD
1
2
24
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 https://t.co/8jel3RrRfc
1
3
52